History

Cytomel (liothyronine sodium) has been FDA-approved since 1956 (NDA 010379; first marketed May 8, 1956) — a genuinely approved prescription medicine, not an unapproved or "research" compound. Its approved indications are replacement therapy in primary, secondary, and tertiary hypothyroidism; TSH suppression as an adjunct to surgery or radioiodine in well-differentiated thyroid cancer; and use as a diagnostic agent in thyroid suppression tests. The FDA label carries a boxed warning that thyroid hormones, including Cytomel, should not be used for the treatment of obesity or weight loss — they are ineffective for weight reduction in euthyroid people, and larger doses may produce serious or life-threatening toxicity, particularly when combined with sympathomimetic amines used as anorectics.

Liothyronine gets pulled into “peptide” and “research chemical” conversations in fitness circles, but it is neither. It is synthetic T3 — the more active of the body’s two main thyroid hormones — and it has been a legitimate, FDA-approved prescription drug under the brand name Cytomel since 1956. That matters, because the honest story here is unusual: at proper, monitored doses, liothyronine has a reassuring safety profile. The danger lies almost entirely in unsupervised overdose. This page is educational and harm-reduction oriented and contains no doses, cycles, stacks, or post-cycle protocols.

What it is

Liothyronine is synthetic L-triiodothyronine (T3), the more biologically active of the two main thyroid hormones (the other being T4/thyroxine). Cytomel is the long-standing US brand (liothyronine sodium); generics exist. It is a small-molecule hormone — not a peptide and not a steroid.

Mechanistically, T3 — whether taken as liothyronine or produced naturally by peripheral deiodination of T4 — diffuses into cells, enters the nucleus, and binds nuclear thyroid hormone receptors (TRα, TRβ) on thyroid-response elements of DNA. This regulates gene transcription, increasing basal metabolic rate, oxygen consumption, thermogenesis, heart rate and contractility, and lipid and carbohydrate turnover, and it supports CNS and skeletal development. Pharmacologically, T3 differs from levothyroxine (T4) by being faster-onset and shorter-acting: it does not require deiodination to become active, so its effects — including cardiac and metabolic ones — appear within hours, and serum/TSH levels swing more sharply.

The claims

Medically, liothyronine is mostly second-line. Standard hypothyroidism care is levothyroxine (T4) monotherapy; T3 is used as an add-on (T4+T3 combination) for a minority of patients with persistent symptoms, in some thyroid-cancer protocols that exploit its rapid washout before scanning, and in myxedema coma (IV form). Because of its short half-life and sharp peaks, careful dosing and monitoring are required, especially in older or cardiac patients.

By athletes and bodybuilders, T3 is used off-label and illicitly chiefly as a fat-loss or “cutting” agent — exploiting the rise in metabolic rate to lean out, often pre-contest. Some users wrongly believe it amplifies anabolic-steroid effects or counters the metabolic slowdown of dieting. This is non-medical use of a prescription drug, typically obtained without a prescription.

What the evidence actually shows

For its core medical question, the human evidence is strong and consistent.

Combination LT4+LT3 for hypothyroidism does not reliably beat LT4 alone. Multiple RCTs and systematic reviews find combination therapy does not reliably improve quality of life, mood, fatigue, or cognition over levothyroxine monotherapy for most patients. The Grozinsky-Glasberg 2006 meta-analysis (11 RCTs, 1,216 patients) concluded T4 monotherapy should remain the treatment of choice, and a later systematic review (Fischman & Domínguez 2018) found combination therapy “has minimal or no effect on fatigue and quality of life.” A subset of symptomatic patients may benefit, and some crossover trials show improvement in selected individuals with residual symptoms, but population-level benefit is unproven.
Properly dosed therapeutic LT3 looks safe. A 2025 JCEM multisource meta-analysis (Bahl et al.) pooling roughly 13,000 LT3 users found no excess atrial fibrillation (RR 1.10, 95% CI 0.74–1.63) and, in pooled cohorts, lower mortality versus LT4-only (RR 0.70, 95% CI 0.62–0.78) — an association, not necessarily causal. Critically, serious adverse events were “almost exclusively linked to supratherapeutic LT3 exposure” — compounding or dispensing errors, unregulated online procurement, or misuse for weight loss and bodybuilding, often at “doses 10 to 1000 times above therapeutic levels.” That is the central honest takeaway: properly dosed, monitored LT3 appears safe; the danger is in overdose and unsupervised use.
No good case for performance enhancement. A 2022 JCEM review (Gild et al.) concludes that evidence for a performance benefit is lacking, that prohibiting thyroid hormone in elite sport is “neither justified nor feasible,” and that excess thyroid hormone is more likely detrimental to health and performance.

Legal and regulatory status

In the United States, liothyronine/Cytomel is a prescription (Rx-only) drug and is not a DEA-controlled substance. It is legal with a valid prescription; obtaining or distributing it without one is unlawful, but it is not scheduled.

For honest contrast with other compounds in the “PED-support” space:

DNP (2,4-dinitrophenol) is not approved and is documented as “unfit for human consumption” — the FDA banned it as a weight-loss agent in the 1930s. It is an industrial chemical with a long history of fatal poisonings, sold illicitly for fat loss.
Mesterolone and fluoxymesterone are anabolic-androgenic steroids and Schedule III controlled substances under the Controlled Substances Act and Anabolic Steroid Control Act (both specifically named in 21 CFR 1308.13).

Anti-doping (WADA 2026). Thyroid hormones — liothyronine/T3 and levothyroxine/T4 — are not prohibited by WADA, in or out of competition. WADA has repeatedly declined to ban them, citing a lack of plausible evidence that exogenous thyroid hormone outside medical indication is performance-enhancing (Gild et al. 2022). For the other named classes, aromatase inhibitors (S4.1), anti-estrogens/SERMs (S4.2), and insulins (S4.4, specifically S4.4.2, Insulins and insulin-mimetics) sit within S4 (Hormone and Metabolic Modulators), while anabolic agents — including anabolic steroids such as fluoxymesterone and mesterolone — are under S1. (Exact sub-section labels should be confirmed against the current 2026 List PDF before publishing.) The 2026 Prohibited List took effect January 1, 2026.

Safety

T3/liothyronine itself. Within-label dosing under monitoring has a reassuring safety profile (the 2025 JCEM meta-analysis). The real risk is dose-driven thyrotoxicosis — far easier to provoke with T3 than with T4 because of its potency, fast onset, and sharp peaks. Non-medical use induces an iatrogenic thyrotoxic / suppressed-TSH state, and those harms are well established:

Cardiovascular events and atrial fibrillation. Collet et al. 2012 (Thyroid Studies Collaboration, individual-participant meta-analysis, 52,674 participants) linked endogenous subclinical hyperthyroidism to increased CHD mortality (HR 1.29, 95% CI 1.02–1.62) and incident atrial fibrillation (HR 1.68, 95% CI 1.16–2.43), with higher risk when TSH was below 0.10 mIU/L. Tachycardia, palpitations, angina, and arrhythmia — and possible precipitation of cardiac events in those with heart disease — are the principal cardiac dangers.
Bone loss and fractures. Blum et al. 2015 (JAMA; Thyroid Studies Collaboration, 70,289 participants) found subclinical hyperthyroidism associated with increased fracture risk (any fracture pooled HR ~1.28, 95% CI 1.06–1.53; hip ~1.36, 95% CI 1.13–1.64; spine ~1.51, 95% CI 0.93–2.45, which is not statistically significant, with markedly higher spine risk when TSH was below 0.10). Excess thyroid hormone accelerates bone turnover and lowers BMD, especially in postmenopausal women.
Other thyrotoxic effects. Heat intolerance and sweating, tremor, weight loss, muscle weakness, anxiety and insomnia — and, with chronic suppression, blunting of the endogenous HPT axis, which takes time to recover. Risk rises with age, cardiovascular disease, and unsupervised “stacking” with stimulants or anorectics (per the boxed warning) or other PEDs.

For honest risk context — other compounds in this space:

DNP — the most dangerous by far. It kills people. It uncouples mitochondrial oxidative phosphorylation, causing uncontrolled heat generation and fatal hyperthermia (core temperatures up to roughly 44 °C). There is no specific antidote or reversal — treatment is supportive only. Deaths are well documented, with poison-center case series reporting roughly a 1-in-8 fatality rate among reported exposures. It is not a thyroid drug and is not medically usable in humans.
Insulin (non-diabetic/unsupervised use): risk of severe, potentially lethal hypoglycemia — seizures, coma, brain injury.
Aromatase inhibitors: lowering estrogen harms bone mineral density and worsens lipid profiles, plus joint symptoms.
SERMs (e.g., tamoxifen/clomiphene used as PED-support): increased risk of venous thromboembolism (clots), plus visual disturbance and mood effects.

None of this is medical advice.

Bottom line

Liothyronine is synthetic T3 — a thyroid hormone, not a peptide and not a steroid. It is a genuinely FDA-approved prescription drug (since 1956), mostly used as second-line thyroid therapy, and misused off-label as a fat-loss agent. The human evidence is strong on two points: combination T4+T3 does not reliably beat T4 alone for hypothyroidism, and properly dosed, monitored LT3 has a reassuring safety profile, with serious harms almost exclusively tied to overdose. In the US it is prescription-only and not a controlled substance, and it is not banned in sport. The real danger is dose-driven thyrotoxicosis — atrial fibrillation, accelerated bone loss, and cardiac strain — which T3 provokes far more readily than T4, and which is far more likely under unsupervised, off-label use.

Evidence grade: Strong human. Strong, consistent human evidence on its medical use and on the safety of properly dosed LT3; the harms of non-medical use are well established from large thyrotoxicosis cohorts.

Liothyronine (T3, Cytomel)